Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics

Circulation Research

Volumn 80, Issue 1, 1997, Pages 11-20

  Hirono, Satoru ^a   Islam, M Omedul ^a   Nakazawa, Mikio ^a   Yoshida, Yutaka ^a   Kodama, Makoto ^a   Shibata, Akira ^a   Izumi, Tohru ^a   Imai, Shoichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

aminoguanidine; cardiomyopathy; hemodynamics; myocarditis; nitric oxide synthase

Indexed keywords

AMINOGUANIDINE; CITRULLINE; MYOSIN; NITRIC OXIDE SYNTHASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ETIOLOGY; GENE EXPRESSION; GIANT CELL; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE NECROSIS; HEART PERFORMANCE; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031022821     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.80.1.11     Document Type: Article

References (62)

1. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancer. 1991;338:1557-1558.
2. De Belder AJ, Radomski MW, Why HJF, Richardson PJ, Bucknall CA, Salas E, Martin JF, Moncada S. Nitric oxide synthase activities in human myocardium. Lancet. 1993;341:84-85.
3. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS. Increased nitric oxide production in heart failure, Lancet. 1994;344:373-374.
4. Yang X, Chowdhury N, Cai B, Brett J, Marboe C, Sciacca RR, Michler RE, Cannon PJ. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest. 1994;94:714-721.
5. Worrall NK, Lazenby WD, Misko TP, Lin T-S, Rodi CP, Manning PT, Tilton RG, Williamson JR, Ferguson TB Jr. Modulation of in vivo allorcactivity by inhibition of inducible nitric oxide synthase, J Exp Med. 1995;181:63-70.
6. Corbett JA, Mikhael A, Shimizu J, Frederick K, Misko TP, McDaniel ML, Kanagawa O, Unanue ER, Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. Proc Natl Acad Sci U S A. 1993;90:8992-8995.
7. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie Q, Nathan CF, Wahl SM, Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med. 1993;178:749-754.
8. Cross AH, Misko TP, Lin RF, Hiekey WF, Trotter JL, Tilton RG, Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice, J Clin Invest. 1994;93:2684-2690.
9. Grisham MB, Specian RD, Zimmerman TE, Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther. 1994;271:1114-1121.
10. Moncada S, Higgs A, The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
11. Drapier J-C, Hibbs JB Jr. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol. 1988;140:2829-2838.
12. Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today. 1992;13:157-160.
13. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575-580.
14. Brady AJB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol. 1992;263:H1963-H1966.
15. O'Connell JB, Renlund DG. Myocarditis and specific myocardial diseases. In: Schlant RC, Alexander RW, eds. Hurst's The Heart. New York, NY: McGraw-Hill Publishing Co; 1994:1591-1597.
16. Reyes MP, Lerner AM, Coxsackievirus myocarditis - with special reference to acute and chronic effects. Prog Cardiovasc Dis. 1985;27:373-394.
17. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE, the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269-275.
18. Rozkovec A, Cambridge G, King M, Hallidie-Smith KA. Natural history of left ventricular function in neonatal coxsackie myocarditis, Pediatr Cardiol. 1985;6:151-156.
19. Dec GW Jr. Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC-S, Johnson RA. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N Engl J Med. 1985;312:885-890.
20. Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation. 1994;89:2421-2432.
21. Lange LG, Schreiner GF. Immune mechanisms of cardiac disease. N Engl J Med. 1994;330:1129-1135.
22. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunapathol. 1990;57:250-262.
23. Kodama M, Matsumoto Y, Fujiwara M, Zhang S, Hanawa H, Itoh E, Tsuda T, Izumi T, Shibata A. Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. Circ Res. 1991;69:1042-1050.
24. Wilson MS, Barth RF, Baker PB, Unverferth DV, Kolibash AJ. Giant cell myocarditis. Am J Med. 1985;79:647-652.
25. Theaker JM, Gatter KC, Heryet A, Evans DJ, McGee JO. Giant cell myocarditis: evidence for the macrophage origin of the giant cells. J Clin Pathol. 1985;38:160-164.
26. Davidoff R, Palacios I, Southern J, Fallon JT, Newell J, Dec GW. Giant cell versus lymphocytic myocarditis -a comparison of their clinical features and long-term outcomes. Circulation. 1991;83:953-961.
27. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 1994;75:278-284.
28. Misko TP, Moore WM, Kasten TP, Nickols GA, Gotten JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG, Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol. 1993;233:119-125.
29. Griffiths MJD, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol. 1993;110:963-968.
30. Hanawa H, Kodama M, Zhang S, Izumi T, Shibata A, An immuno-suppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats, Clin Immunol Immunopathol. 1992;62:321-326.
31. Kodama M, Zhang S, Hanawa H, Saeki M, Inomata T, Suzuki K, Koyama S, Shibata A. Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat. Circulation. 1995;91:1116-1122.
32. Knowles RG, Merrett M, Salter M, Moneada S. Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat, Biochem J. 1990;270:833-836.
33. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83:346-356.
34. 2+ pump ATPase of vascular smooth muscle via phosphorylation of a 240-kDa protein. J Biol Chem. 1991;266:19819-19825.
35. Yamamoto T, Sasaki S, Fushimi K, Ishibashi K, Yaoita E, Kawasaki K, Marumo F, Kihara I, Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. Am J Physiol. 1995;268:C1546-C1551.
36. Stuehr DJ, Nathan CF, Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med. 1989;169:1543-1555.
37. Drapier J-C, Hibbs JB Jr, Murine cytotoxic activated macrophages inhibit aconitase in tumor cells: inhibition involves the iron-sulfur prosthetic group and is reversible. J Clin Invest. 1986;78:790-797.
38. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992;258:1898-1902.
39. Balligand J-L, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347-351.
40. Hirono S, Hanawa H, Kodama M, Shibata A, Nakazawa M, Imai S, Izumi T. Expression of inducible nitric oxide synthase in the myo- cardiuin of rats with experimental autoimmune myocarditis. Jpn Circ J. 1996;60:405P, Abstract.
41. Kodama M, Matsumoto Y, Fujiwara M. In vivo lymphocyte-mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis, Circulation. 1992;85:1918-1926.
42. Suzuki K. A histological study on experimental autoimmune myocarditis with special reference to initiation of the disease and cardiac dendritic cells. Virchows Arch. 1995;426:493-500.
43. o-monomethyl-L-arginine: a role for cyclic GMP. Blood. 1989;74:1885-1887.
44. Belenky SN, Robbins RA, Rennard SI, Gossman GL, Nelson KJ, Rubinstein I, Inhibitors of nitric oxide synthase attenuate human neutrophil chemotaxis in vitro. J Lab Clin Med. 1993;122:388-394.
45. Belenky SN, Robbins RA, Rubinstein I. Nitric oxide synthase inhibitors attenuate human monocytc chemotaxis in vitro. J Leukoc Biol. 1993;53:498-503.
46. Worrall NK, Chang K, Suau GM, Allison WS, Misko TP, Sullivan PM, Tilton RG, Williamson JR, Ferguson TB Jr. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Circ Res. 1996;78:769-779.
47. Laslo F, Evans SM, Whittle BJR, Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur J Pharmacol. 1995;272:169-175.
48. Corbett JA, Tilton RG, Chang K, Hasan KS, Mo Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41:552-556.
49. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD, Feussner KD. Distribution and properties of human intestinal diamine oxide and its relevance for the histamine catabolism. Biochim Biophys Acta. 1983;756:196-203.
50. Kumari K, Umar S, Bansal V, Sahib MK. Monoaminoguanidine inhibits aldose reductase. Biochem Pharmacol. 1991;41:1527-1528.
51. Seiler N, Bolkenius FN, Knödgen B. The influence of catabolic reactions on polyamine excretion. Biochem J. 1985;225:219-226.
52. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci U S A. 1992;89:6876-6880.
53. Edelstein D, Brownlee M, Mechanistic studies of advanced glyco sylation end product inhibition by aminoguanidine. Diabetes. 1992;41:26-29.
54. Levi RC, Alloatti G, Fischmeister R, Cyclic GMP regulates the Cachannel current in guinea pig ventricular myocytes. Eur J Physiol. 1989;413:685-687.
55. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Prof Natl Acad Sci USA. 1991;88:1197-1201.
56. Watanabe AM, Besch HR Jr. Interaction between cyclic adenosine monophosphate and cyclic guanosine monophosphate in guinea pig ventricular myocardium. Circ Res. 1975;37:309-317.
57. Shah AM, Lewis MJ. Modulation of myocardial contraction by endocardinal and coronary vascular endothelium. Trends Cardiovasc Med. 1993;3:98-103.
58. Ishibashi T, Hamaguchi M, Kato K, Kawada T, Ohta H, Sasnge H, Imai S. Relationship between myoglobin contents and increases in cyclic GMP produced by glyceryl trinitrate and nitric oxide in rabbit aorta, right atrium and papillary muscle. Arch Pharmacol. 1993;347:553-561.
59. Hughes SR, Williams TJ, Brain SD. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur. J Pharmacol. 1990;191:481-484.
60. Ialenti A, Ianaro A, Moncada S, Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol. 1992;211:177-182.
61. Sagar KB, Hastillo A, Wolfgang TC, Lower RR, Hess ML, Left ventricular mass by M-mode echocardiography in cardiac transplant patients with acute rejection. Circulation. 1981;64(suppl II):II-216-II-220.
62. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651-4655.